Preclinical Evaluation of Antitumor Efficacy of a New Radiopharmaceutical Based on Thermoresponsive Carrier and Samarium-153

Petriev V.M.¹², Tishchenko V.K.¹, Smoryzanova O.A.¹, Bol’bit N.M.³, Duflot V.R.³, Morozova N.B.⁴, and Yakubovskaya R.I.⁴

¹Tsyb Medical Radiological Research Centre, Obninsk, Russia
²National Research Nuclear University MPEI (Moscow Engineering Physics Institute), Kashirskoe shosse 31, Moscow, 115409, Russia
³JSC «Karpov Institute of Physical Chemistry», Obninsk, Russia
⁴Moscow Hertsen Research Institute of Oncology, Moscow, Russia

Abstract

This work is devoted to studying the in vivo antitumor efficacy of the new injection radiopharmaceutical based on thermoresponsive polymer and β⁻-emitting radionuclide samarium-153 (¹⁵³Sm-KARP-CheM).

The study of in vivo antitumor efficacy was performed using mice F1 and C57Bl/6 with transplanted subcutaneously sarcoma S37 and melanoma B16, respectively. The animals received single intratumoral bolus injections of 37 MBq (1 mCi), or 18.5 MBq (0.5 mCi) of ¹⁵³Sm-KARP-CheM, or saline in a volume 0.1 ml. The efficacy of antitumor treatment was evaluated using tumor growth inhibition index (TGI, %) and increase of average life span (ILS, %).

The most meaningful therapeutic efficacy after intratumoral injection of ¹⁵³Sm-KARP-CheM was observed in melanoma-bearing mice C57Bl/6. The highest values of TGI for melanoma B16 were 79.5% and 79.6% after treatment with 18.5 MBq or 37 MBq, respectively. An increase of average life span by 17.1% was found in group of melanoma-bearing mice treated with 37 MBq of ¹⁵³Sm-KARP-CheM only. Tumor growth inhibition of sarcoma S37 was slightly lower as compared with melanoma B16: 62.5% and 59.0% in 37 MBq and 18.5 MBq groups, respectively. ¹⁵³Sm-KARP-CheM didn’t increase average life span of treated animals. In conclusion, ¹⁵³Sm-KARP-CheM seems to be effective radiopharmaceutical for local tumor radiotherapy.

Keywords: thermoresponsive polymer, samarium-153, radionuclide therapy of cancer, sarcoma S37, melanoma B16, antitumor efficacy.
1. Introduction

Nowadays the search of new approaches for cancer therapy is still continued. Local injectable radiotherapy is one of the promising method of solid tumors treatment. An intratumoral administration of labeled compound allows for depositing high radiation doses directly in the application site and keeping the whole-bode doses low.

Radiolabeled thermoresponsive, sometimes also called thermosensitive polymers attract much attention due to their cloud-point temperature values close to human body temperature [1, 2]. In case the environment is heated above 37 °C, the polymer chains hydrate, become more hydrophobic, and finally collapse. It immediately leads to a high amount of radioactivity at the desired site of action, and avoids systemic adverse effects. Futhermore, in intratumoral radionuclide therapy the radionuclide does not need to be internalized by tumor cells to achieve efficacy, because the radioactive emissions can kill tumor cells from a distance.

One of the well-known and widely studied polymer is poly(N-isopropylacrylamide) (PNIPAM) because of its well defined structure and property specially its temperature response is closed to human body [3]. It is not cytotoxic for any of human cell lines even at high concentration, and its excretion occurred via urine and faeces [4, 5].

Samarium-153 (153Sm) is an appropriate radionuclide for radiotherapy of cancer. 153Sm emits beta particles with maximum energy of 0.81 MeV, mean energy of 0.58 MeV. The mean range of energy deposition is 0.6 mm, while the maximum range is 2.5 mm. The physical half-life of 153Sm is 46.3 hours (1.9 days). It also emits a 103-keV gamma radiation, which allows imaging of biodistribution of labeled compound with conventional gamma-cameras.

The aim of this study was to evaluate an antitumor efficacy of a new designed thermoresponsive system based on the copolymers of N-isopropylmethacrylamide with allylamine labeled with 153Sm for local radiotherapy.

2. Methods and materials

The in vivo antitumor efficacy of 153Sm-CARP-CheM was assessed using C57Bl/6 mice with melanoma B16 xenograft tumors and F1 mice with sarcoma S-37 xenograft tumors. When the tumor volumes reached 70-90 mm³, 30 C57Bl/6 mice were randomized into 3 groups, and 30 F1 mice were also randomly separated into 3 groups. Each groups of animals were intratumoral injected with 37 MBq (1 mCi), or 18.5 MBq (0.5 mCi) of 153Sm-CARP-CheM, or saline in a volume 0.1 ml. Tumor size was determined
twice a week by measuring the length, width, and depth of the tumor using a caliper. Tumor volume was calculated as follows: tumor volume = (length \times width \times depth) \times \pi/6.

The efficacy of antitumor treatment was evaluated using tumor growth inhibition index (TGI, %) and increase of average life span (ILS, %). TGI was defined as:

\[
TGI = \left( 1 - \frac{\text{Mean volume of treated tumors}}{\text{Mean volume of control tumors}} \right) \times 100\%.
\]

ILS was defined as:

\[
ILS = \left( 1 - \frac{\text{Average life span of treated animals}}{\text{Average life span of control animals}} \right) \times 100\%.
\]

The results of mean tumor volume and average life span for each group of mice were expressed as mean value and standard error of the mean (M ± m). Student’s \(t\) test was used to analyze data throughout all studies between groups, and \(p<0.05\) was considered statistically significant.

3. Results

Antitumor efficacy of \(^{153}\text{Sm-CARP-CheM}\) was assessed in tumor-bearing mice with different tumor histogenesis: melanoma B16 and sarcoma S-37. According to the results, intratumoral injection of \(^{153}\text{Sm-CARP-CheM}\) considerably inhibited tumor growth of melanoma B16 and sarcoma S-37. The most significant effect was observed in melanoma B16 tumor-bearing mice: intratumoral injection of \(^{153}\text{Sm-CARP-CheM}\) delayed tumor growth as compared with control group at 4 days after treatment (Fig. 1). There were no significant differences between 37 MBq and 18.5 MBq groups. It was evident that the tumor volume for control mice increased 32-fold to 3680.1 mm\(^3\) while the tumor volume of mice treated with 37 MBq or 18.5 MBq of \(^{153}\text{Sm-CARP-CheM}\) increased 15-fold only (Fig. 1). TGI index varied from 55.4% to 79.6% in 37 MBq treated group, and from 55.3% to 79.5% in 18.5 MBq treated group of melanoma-bearing mice (Table 1).

In mice F1 with subcutaneous transplanted sarcoma S-37 significant tumor growth inhibition was revealed only at 11-14 days after treatment (Figure 1, Table 1). The tumor volume increased 12-fold and 23-fold throughout the study in 37 MBq and 18.5 MBq treated groups, respectively, and 36-fold in control group. In 18.5 MBq group of mice the highest TGI index (62.5%) was observed at 14 day after \(^{153}\text{Sm-CARP-CheM}\) injection, whereas in 37 MBq group TGI index was reached the highest value (59.0%) by the end of the study.
Figure 1: Mean tumor volume after intratumoral administration of 37 MBq and 18.5 MBq of $^{153}$Sm-CARP-CheM, or saline: A – mice C57Bl/6 with subcutaneous transplanted melanoma B16; B – mice F1 with subcutaneous transplanted sarcoma S-37.

Table 1: Antitumor efficacy of $^{153}$Sm-CARP-Chem.

<table>
<thead>
<tr>
<th>Tumor</th>
<th>Injected activity</th>
<th>TGI, %</th>
<th>Average life span, days</th>
<th>ILS, %</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Days after treatment</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>4</td>
<td>7</td>
<td>11</td>
</tr>
<tr>
<td>Melanoma B16</td>
<td>37 MBq</td>
<td>55.4%</td>
<td>72.1%</td>
<td>79.6%</td>
</tr>
<tr>
<td>Sarcoma S37</td>
<td>-</td>
<td>9.0%</td>
<td>33.2%</td>
<td>57.5%</td>
</tr>
<tr>
<td>Melanoma B16</td>
<td>18.5 MBq</td>
<td>63.8%</td>
<td>79.5%</td>
<td>70.7%</td>
</tr>
<tr>
<td>Sarcoma S37</td>
<td>-</td>
<td>19.0%</td>
<td>47.9%</td>
<td>62.5%</td>
</tr>
<tr>
<td>Melanoma B16</td>
<td>Saline (control group)</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Sarcoma S37</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

*p<0.05 as compared with control group

Average life span of melanoma B16 bearing mice treated with 37 MBq of $^{153}$Sm-CARP-CheM was 24.6 days versus 21.0 days in control group (p<0.05), and ILS was 17.1%. In contrast, average life span in 18.5 MBq group decreased by 29% as compared with control group and didn’t exceed 14.9 days (Table 1).

In mice with sarcoma S-37 average life span was 37.5 days and 36.6 days in 37 MBq and 18.5 MBq groups, respectively. There were no significant differences between the average life span in both treated groups of mice F1 with sarcoma S-37 and control...
group. The values of ILS were only 6.8% and 4.3% in groups that received 37 MBq or 18.5 MBq of $^{153}\text{Sm}$-CARP-CheM, respectively (Table 1).

4. Conclusion

Intratumoral injection of $^{153}\text{Sm}$-CARP-CheM considerably inhibited tumor growth of melanoma B16 and sarcoma S-37. The most significant effect was observed in melanoma B16 tumor-bearing mice: TGI index reached 79.6% and 79.5% in 37 MBq and 18.5 MBq treated groups, respectively. Tumor growth inhibition of sarcoma S37 was slightly lower as compared with melanoma B16: 62.5% and 59.0% in 37 MBq and 18.5 MBq groups, respectively. Dose-dependent tumor growth suppression didn’t observe. $^{153}\text{Sm}$-KARP-CheM didn’t increase significantly average life span of treated animals. In conclusion, the suppression of tumor growth suggested that this compound has exciting potential for local tumor therapy.

References